STAT+: Pharmalittle: We’re reading about a U.S. rule on Chinese deals, Belgium refusing Mounjaro coverage, and more
U.S. is poised to issue a proposed rule that would subject outbound licensing deals with Chinese biotech companies to additional scrutiny
The U.S. Department of Treasury is set to release a proposed rule on Thursday that would require additional regulatory oversight for outbound licensing deals between American and Chinese biotech firms, according to Endpoints News. The Comprehensive Outbound Investment National Security Act, enacted in December 2015, subjects certain American investments in Chinese technology to Treasury screening.
This new rule may face challenges due to concerns surrounding China's ambitions and the prevailing anti-pharma sentiment in some congressional and administrative circles. Analyst Rob Smith from Capital Alpha Partners suggests that the pharmaceutical industry might encounter significant obstacles in overcoming these objections.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
